相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial
Y. Iwamoto et al.
DIABETES OBESITY & METABOLISM (2010)
Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
Yasuhiko Iwamoto et al.
ENDOCRINE JOURNAL (2010)
GIP and GLP-1, the two incretin hormones: Similarities and differences
Yutaka Seino et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls
Daisuke Yabe et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Impact of Sitagliptin on Markers of β-cell Function: A Meta-Analysis
Daniel M. Riche et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2009)
Secretory unit of islet in transplantation (SUIT) and engrafted islet rate (EIR) indexes are useful for evaluating single islet transplantation
Hirofumi Noguchi et al.
CELL TRANSPLANTATION (2008)
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
Kenji Nonaka et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
K. Hermansen et al.
DIABETES OBESITY & METABOLISM (2007)
Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
Markolf Hanefeld et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin
G. A. Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes
R. Scott et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2007)
SUIT, secretory units of islets in transplantation: An index for therapeutic management of islet transplanted patients and its application to type 2 diabetes
Yuichiro Yamada et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2006)
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes
Pablo Aschner et al.
DIABETES CARE (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone
Bernard Charbonnel et al.
DIABETES CARE (2006)
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
Gary A. Herman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Julio Rosenstock et al.
CLINICAL THERAPEUTICS (2006)
Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects
Gary A. Herman et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers
AJ Bergman et al.
CLINICAL THERAPEUTICS (2006)
Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses
GA Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Biological actions and therapeutic potential of the glucagon-like peptides
DJ Drucker
GASTROENTEROLOGY (2002)
分享论文
